Tirzepatide

Dual incretin receptor agonists are among the most heavily studied structures in current peptide pharmacology. Questions examined in the published literature include:

• Relative potency and signalling bias at GIPR versus GLP-1R, and how substitution patterns shift that balance
• Recruitment of G-protein versus beta-arrestin pathways and the resulting receptor internalisation profiles
• cAMP signalling kinetics in receptor-transfected cell lines
• How albumin-binding acylation changes half-life and exposure in preclinical species
• Structural work resolving how one ligand accommodates two distinct receptor binding pockets

Each item describes an area of ongoing scientific investigation. No claim is made about any effect in humans, and this material is sold for in vitro and preclinical laboratory use only.